Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021239949 - HUMAN RECOMBINANT MONOCLONAL ANTIBODY AGAINST SARS-COV-2 SPIKE GLYCOPROTEIN

Publication Number WO/2021/239949
Publication Date 02.12.2021
International Application No. PCT/EP2021/064352
International Filing Date 28.05.2021
IPC
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
CPC
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
C07K 2317/92
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
90characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applicants
  • DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E. V. (DZNE) [DE]/[DE]
  • CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN [DE]/[DE]
Inventors
  • KREYE, Jakob
  • PRÜSS, Harald
  • REINCKE, S. Momsen
  • KORNAU, Hans-Christian
  • SANCHEZ-SENDIN, Elisa
  • WENDISCH, Daniel
  • MÜLLER, Marcel Alexander
  • SANDER, Leif Erik
  • CORMAN, Victor Max
Agents
  • HERTIN UND PARTNER RECHTS- UND PATENTANWÄLTE
Priority Data
20177437.929.05.2020EP
20182069.324.06.2020EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) HUMAN RECOMBINANT MONOCLONAL ANTIBODY AGAINST SARS-COV-2 SPIKE GLYCOPROTEIN
(FR) ANTICORPS MONOCLONAL RECOMBINANT HUMAIN DIRIGÉ CONTRE LA GLYCOPROTÉINE DE SPICULE DE SARS-COV-2
Abstract
(EN) The disclosure relates to a human recombinant monoclonal antibody or antibody fragment that binds the receptor binding domain (RBD) of the S1 subunit (S1) of a Spike glycoprotein of SARS-CoV-2, wherein the heavy and light chain variable amino acid sequences of the antibody (VH and VL) were isolated from convalescent COVID-19 patients. In further aspects, the disclosure relates to a nucleic acid molecule encoding an antibody or antibody fragment of the disclosure, a host cell comprising the nucleic acid molecule, and a pharmaceutical composition comprising an antibody or antibody fragment of the disclosure. The disclosure further relates to corresponding medical uses and therapeutic methods of administering an antibody or antibody fragment of the disclosure in the treatment and/or prevention of a medical condition associated with a SARS Coronavirus, in addition to diagnostic uses and methods.
(FR) La divulgation concerne un anticorps monoclonal recombinant humain ou un fragment d'anticorps qui se lie au domaine de liaison au récepteur (RBD) de la sous-unité S1 (S1) d'une glycoprotéine de spicule du SARS-CoV-2, les séquences d'acides aminés variables de chaîne lourde et de chaîne légère de l'anticorps (VH et VL) étant isolées à partir de patients atteints de COVID-19 en convalescence. Dans d'autres aspects, la divulgation concerne une molécule d'acide nucléique codant pour un anticorps ou un fragment d'anticorps selon l'invention, une cellule hôte comprenant la molécule d'acide nucléique, et une composition pharmaceutique comprenant un anticorps ou un fragment d'anticorps selon l'invention. La divulgation concerne en outre des utilisations médicales correspondantes et des méthodes thérapeutiques d'administration d'un anticorps ou d'un fragment d'anticorps selon l'invention dans le traitement et/ou la prévention d'un état médical associé au SARS Coronavirus, ainsi que des utilisations et des méthodes de diagnostic.
Latest bibliographic data on file with the International Bureau